Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2673MR)

This product GTTS-WQ2673MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2673MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7112MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ1100MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ5442MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ9588MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ208MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ6611MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ8493MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ1057MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW